The aim of our study was to evaluate whether an association exists between weekday (WD) or weekend (WE) admission
selleck and mortality for patients with ARRD.
Methods: Based on the database of routinely collected hospital admissions of the region of Emilia Romagna (RER) of Italy, we examined the discharge sheets of all patients with AARD (January 1999 to December 2009). The risk of in-hospital death was calculated for admissions on the WE compared with the admissions during a WD.
Results: The analysis considered 4559 events in 4461 patients. AARD admissions were most frequent on Monday (14.7%) and Friday (14.8%) and less frequent on Saturday (12.6%). The percentage of events admitted on Sunday/holiday was 15.0%, whereas the distribution of death rate with respect to day of admission was significantly different (chi(2) = 23.472; P < .001) with the highest frequency peak on Sunday/holiday (17.4%) and the lowest on Tuesday (12.9%). WE admissions were associated with significantly higher in-hospital mortality (43.4%) than WD admissions (36.9%, P < .001). Multivariate regression analysis showed that WE admission was an independent risk factor for increased in-hospital mortality odds ratio 1.318; 95% confidence interval, 1.144-1.517; P < .001).
Conclusions: Our findings
show that hospitalization for AARD on WE is associated JQ-EZ-05 purchase with a significantly higher mortality rate than hospitalization on WD. Further studies are needed to investigate whether ensuring optimal diagnostic and therapeutic approaches during the entire week might improve the overall
survival of patients with ARRD. (J Vasc Surg 2012;55:1247-54.)”
“Several studies demonstrated reduced CSF alpha-synuclein values in patients with advanced Parkinson’s disease (PD). Values in drug-naive PD subjects ADP ribosylation factor and healthy controls (HC) have not yet been reported. We measured CSF values including alpha-synuclein in a cohort of 78 previously untreated PD patients and 48 HC subjects. Measurements of total alpha-synuclein concentrations were performed using two independently operated immunoassays, i.e., one academia-based and previously validated (ELISA 1), the other industry-based, renewable and commercially available (ELISA 2). Mean values for CSF a-synuclein were significantly lower in de novo PD patients when compared to HC subjects, as demonstrated by both assays (ELISA 1, p = 0.049; ELISA 2, p = 0.005; combined, p = 0.002). Using the renewable ELISA 2, CSF alpha-synuclein concentrations of 1884.31 pg/ml or less showed a sensitivity of 0.91 and a specificity of 0.25 for the diagnosis of Parkinson’s disease. The corresponding area-under-the-curve value was 0.65 (confidence interval, 0.554-0.750), which was statistically significant (p = 0.004).